← Human Trials & Peer-Reviewed Studies
Systemic and renal effects of atrial natriuretic peptide in patients with heart failure treated with angiotensin-converting enzyme inhibitor or in acute saline solution loading
Plain-language guide to PMID 11231440 (2001): crossover randomized controlled trial study of ANP (Atrial Natriuretic Peptide).
Key Facts
- PMID
- 11231440
- Journal
- American heart journal
- Year
- 2001
- Study type
- Randomized Controlled Trial
- Authors
- Tomiyama H et al. (6 authors)
- DOI
- 10.1067/mhj.2001.112782
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of ANP (Atrial Natriuretic Peptide), published as a randomized controlled trial.
Their purpose was to study the effects of atrial natriuretic peptide (ANP) on cardiorenal functions when it is used to manage patients with heart failure who are receiving an angiotensin-converting enzyme inhibitor (ACEi) or in acute saline solution loading.
Who Took Part
The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.
Seventeen patients with mild to moderate heart failure were entered into protocol 1 or 2.
How the Study Was Run
The researchers set it up as a randomized and crossover study.
Because people in this ANP (Atrial Natriuretic Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
In the crossover set-up each of the participants took both ANP (Atrial Natriuretic Peptide) and the comparison in turn, acting as their own control.
Protocol 2 was acute saline loading with or without coadministration of ANP (n = 8).
In both protocols cardiorenal hemodynamics and urinary sodium excretion were assessed before and after each intervention.
What Was Measured
The subject headings attached to it are Angiotensin-Converting Enzyme Inhibitors, Atrial Natriuretic Factor, Glomerular Filtration Rate, Heart, Heart Failure, Kidney and Microcirculation.
What This Means in Plain Language
The paper is a randomized and crossover study of ANP (Atrial Natriuretic Peptide).
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2001 (American heart journal), a journal based in United States.
More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.
Our Notes on the Compound
ANP (Atrial Natriuretic Peptide): A 28-amino-acid heart hormone that relaxes blood vessels and increases salt excretion; carperitide is a recombinant form.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.